On March 3, 2026, Teva Pharmaceuticals and Blackstone Life Sciences announced a $400 million strategic funding agreement to accelerate the clinical development of duvakitug. This experimental monoclonal antibody is currently in Phase III trials, positioning itself as a potential breakthrough for patients suffering from ulcerative colitis (UC) and Crohn’s disease (CD).
Under this four-year strategic agreement, Blackstone Life Sciences will provide Teva with $400 million to cover ongoing and future development costs. In exchange, Blackstone is eligible for a milestone payment upon FDA approval, subsequent commercial milestones, and low single-digit global royalties on net sales. This partnership aligns with Teva’s “Pivot to Growth” strategy, aiming to advance its high-potential pipeline through capital-efficient collaborations.
Duvakitug targets TL1A, a protein believed to drive both inflammation and fibrosis within the gastrointestinal tract. By addressing the biological drivers of tissue scarring and intestinal obstruction—major complications for the 4.9 million IBD patients worldwide—duvakitug is being developed as a potential best-in-class therapy. Teva continues to co-develop this asset with Sanofi, with a global commercialization plan already in place pending regulatory clearance.